Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib in IDH1-mutated myelodysplastic syndrome
2017-003681-27Phase 2Active
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ivosidenib in myelodysplastic syndrome (MDS) (3 cohorts), sponsored by Groupe Français des Myélodysplasies. Primary endpoints: Overall hematological response at 3 months (cohorts A and B), Overall hematological response at 6 months (cohorts A and B) and 1 more. Started Oct 2018; status: active.
02
Drugs
ivosidenib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2017-003681-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003681-27.